Sand play to test whether microbe exposure eases eczema in young children
Tests sandbox microbe exposure in children with atopic dermatitis, a form of eczema.
Plain-language title generated from the registry record
Registry title: Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis
Key facts
- Where
- Helsinki and Tampere, FinlandSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 5 years old?
Source: NCT06390696, who can take part
Where in Finland
- Natural Resources Institute FinlandHelsinki, FinlandTaking people
- Tampere UniversityTampere, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Natural Resources Institute Finland
- Trial code
- NCT06390696
- Record updated
- 30 April 2024
- Original description
The prevalence of atopic dermatitis has increased along with urbanization and biodiversity loss. According to biodiversity hypothesis, the main reason is urban lifestyle and reduced contact to microbial diversity. Previous studies indicate association between atopic dermatitis and exposure to natural microbes in childhood.Read full original descriptionShow less
Biodiversity Interventions for Well-being - the Effect of Biodiversity Exposure on Atopic Dermatitis
The prevalence of atopic dermatitis has increased along with urbanization and biodiversity loss. According to biodiversity hypothesis, the main reason is urban lifestyle and reduced contact to microbial diversity. Previous studies indicate association between atopic dermatitis and exposure to natural microbes in childhood.
Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis will investigate whether the exposure to microbial diversity in sandbox reduces the symptoms of atopic dermatitis, alters commensal microbiota and modifies immune regulation in children.
Inclusion: Eczema Area and Severity Index ≥ 2.
Exclusion: Immune deficiencies, i.e., antibody deficiency; Immunosuppressive systematic medications; Topical medication for the treatment of atopic dermatitis during the trial; Non-participation in the national vaccine program; A disease affecting immune response (e.g., colitis ulcerosa, rheumatoid arthritis, Crohn's disease, diabetes); Cancer diagnosis; Disability affecting the immune response (e.g. Down's syndrome); Eczema Area and Severity Index < 2; Participation in another intervention or follow-up study.